Search - tctmd.com

Displaying 341 - 360 of 809

Sort: Relevancy | Date

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

News Daily News

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Yael L. Maxwell

April 28, 2020

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Todd Neale

April 02, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

Presentation ACC 2020

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presenter: Dirk J. Blom

March 30, 2020

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Caitlin E. Cox

March 24, 2020

News Daily News

Better Adherence to Guideline Advice Pays Off After Acute MI

Yael L. Maxwell

March 11, 2020

News Daily News

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

Shelley Wood

February 26, 2020

Presentation JIM 2020

Optimal LDL levels in patients with ACS undergoing PCI

Presenter: Giuseppe Musumeci

February 13, 2020

Presentation JIM 2020

Ultra LOW LDL is the target for high risk patients

Presenter: Francesco Prati

February 13, 2020

Presentation JIM 2020

Optimal LDL Levels In Patients With ACS Undergoing PCI Clinical Case: PCI In ACS Patients With Multivessel Disease

Presenter: Ferdinando Varbella

February 13, 2020

News Daily News

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Yael L. Maxwell

February 12, 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2020

Shelley Wood

January 31, 2020

News Daily News

Earlier, Longer Interventions Proposed for Optimal Population LDL Cholesterol

Yael L. Maxwell

January 28, 2020

News Daily News

Coconut Oil Ups LDL Cholesterol Compared With Other Fats: Meta-analysis

Yael L. Maxwell

January 16, 2020

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

Advertisement

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Better Adherence to Guideline Advice Pays Off After Acute MI

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

Optimal LDL levels in patients with ACS undergoing PCI

Ultra LOW LDL is the target for high risk patients

Optimal LDL Levels In Patients With ACS Undergoing PCI Clinical Case: PCI In ACS Patients With Multivessel Disease

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

TCTMD’s Top 10 Most Popular Stories for January 2020

Earlier, Longer Interventions Proposed for Optimal Population LDL Cholesterol

Coconut Oil Ups LDL Cholesterol Compared With Other Fats: Meta-analysis

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content